Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Glioblastoma Multiforme (GBM) Market Overview, Industry Top Manufactures, Market Size, Industry Growth Analysis & Forecast: 2021

Monday, October 10, 2016 5:45
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Glioblastoma Multiforme (GBM) Market report focuses on the major drivers and restraints for the key players. Glioblastoma Multiforme (GBM) Market research report also provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. Metolazone Market research report is a professional and in-depth study on the current state of the Glioblastoma Multiforme (GBM) Industry.

Glioblastoma Multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is the most common and aggressive human brain tumor, accounting for 15.4% of all primary brain tumors and 60-75% of all astrocytomas. It has a peak incidence between 55 and 84 years of age, with the median age of diagnosis being 64 years. In the US and EU, the annual incidence was estimated to be three to four cases per 100,000 people. GBM has a high degree of intratumoral heterogeneity, which is associated with poor prognosis and the development of drug resistance.

Browse detailed TOC, Tables, Figures, Charts and Companies mentioned in Glioblastoma Multiforme (GBM) Market @

The GBM market is characterized by a small selection of marketed product options, consisting of chemotherapies, cancer immunotherapies and receptor tyrosine kinase inhibitor products. The pipeline is moderately large, with 512 products active across all stages of development. First-in-class products only constitute approximately a quarter of the pipeline, and represent 31% of products with a disclosed target. The most widely studied group of first-in-class targets are the receptor tyrosine kinase and ligand inhibitors, a trend that has been heavily influenced by the success of Avastin, and possibly successful EGFR inhibitors such as Tarceva that are used in the treatment of other oncology indications.

Potential driving factors for the market include a typically poor outcome for treated patients, a growing patient pool if disease prognosis can be improved, a lack of approved options in the market, and a strong understanding of the disease pathophysiology that has developed over the last decade, facilitating the development of novel compounds that may fulfill the unmet needs.

Overall, due to the highly complex and polygenic nature of GBM, which has numerous subtype classifications, it is unlikely that the inhibition of a single target will be sufficient to substantially improve patient prognosis. Instead, it is more likely that the concurrent use of multiple targeted therapies, along with other available modes of therapy, may improve treatment outcomes. First-in-class targets analyzed in this report have shown encouraging efficacy profiles, and some show the ability to chemosensitize cancer cells.

Get PDF Sample of Report @

Reports Covers detailed TOC as follows:

4 Clinical and Commercial Landscape 8

4.1 Disease Overview 8

4.2 Epidemiology 8

4.3 Disease Symptoms 8

4.4 Etiology 9

4.4.1 Age, Rae and Gender 9

4.4.2 Genetic Factors 10

4.4.3 Environmental Factors 10

4.5 Pathophysiology 11

4.5.1 Tumor Initiation and Aberrant Cell Proliferation and Survival 11

4.5.2 Tumor Metabolic Shift 12

4.5.3 Tumor Progression, Micro-environment Alteration and Angiogenesis 12

4.5.4 Cancer Stem Cells 13

4.6 Diagnosis 14

4.7 GBM Prognosis and Prognostic Factors 15

4.8 Classification 15

4.8.1 Loss of Heterozygosity of Chromosome 10 16

4.8.2 Epidermal Growth Factor Receptor Amplification 17

4.8.3 Phosphatase and Tensin Homolog Mutation 17

4.8.4 Loss of p53 Function 17

4.8.5 p16INK4a Alteration and Loss of Normal Retinoblastoma 1 Function 17

4.8.6 Isocitrate Dehydrogenase 1 or Isocitrate Dehydrogenase 2 Mutation 18

4.9 Glioblastoma Multiforme Treatment 18

4.10 Surgery and Radiation Therapy 18

4.11 Overview of Marketed Products for Glioblastoma Multiforme 19

4.11.1 Chemotherapy 20

4.11.2 Targeted Therapies 21

4.12 Treatment Algorithm 21

4.13 Current Unmet Need in the GBM Market 23

5 Assessment of Pipeline Product Innovation 24

5.1 Glioblastoma Pipeline by Phase, Molecule Type and Molecular Target 24

5.2 First-in-Class Pipeline Programs 28

6 Signaling Network, Disease Causation and Innovation Alignment 33

6.1 The Complexity of Signaling Networks in Oncology 33

6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 34

6.3 First-in-Class Target Matrix Assessment 34

7 First-in-Class Target Evaluation 36

7.1 Pipeline Programs Targeting AKT 1 and 2 36

7.2 Pipeline Programs Targeting CDK1/2 37

7.3 Pipeline Programs Targeting PIK3CB and PIK3CG 38

7.4 Pipeline Programs which Target NTRK1 39

7.5 Pipeline Programs Targeting XIAP 41

7.6 Pipeline Programs Targeting Myc 42

7.7 Pipeline Programs Targeting PRKCA 43

7.8 Pipeline Programs which Target CASP8 and CASP9 44

7.9 Pipeline Programs which Target NR4A1 45

7.10 Pipeline Programs Targeting HIF-1α 45

Continue …..


  • The report analyzes innovation in GBM, in the context of the overall pipeline and current market landscape. In addition, it analyzes the deals landscape surrounding first-in-class products, and pinpoints opportunities for in-licensing.
  • A brief introduction to GBM, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms.
  • The changing molecular target landscape between the market and the pipeline, including particular focal points of innovation in the pipeline.
  • A comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
  • Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
  • Assessment of the licensing and co-development deal landscape for GBM therapies.

Need Assistance (Content, Price, Sample and Discount), Ask Experts @

Reasons to buy

  • Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options.
  • Visualize the composition of the GBM market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of the gaps in the current market.
  • Analyze the GBM pipeline, stratified by stage of development, molecule type and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
  • Identify commercial opportunities in the GBM deals landscape by analyzing trends in licensing and co-development deals.

About Absolute Report:

Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.


Mr. Ameya Pingaley

Absolute Reports

+1-408 520 9750

Email –

For Latest News about Current Market Trends and Forecast Visit At:

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.